These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21244767)

  • 1. Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.
    Giordano N; Puccetti L; Papakostas P; Di Pietra N; Bruni F; Pasqui AL; Acampa M; Bocchi V; Donati V; Voglino M; Fioravanti A; Montella A; Auteri A; Nuti R; Pastorelli M
    Int J Immunopathol Pharmacol; 2010; 23(4):1185-94. PubMed ID: 21244767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.
    Kuhn A; Haust M; Ruland V; Weber R; Verde P; Felder G; Ohmann C; Gensch K; Ruzicka T
    Rheumatology (Oxford); 2010 Jul; 49(7):1336-45. PubMed ID: 20371505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.
    Cozzi F; Pigatto E; Rizzo M; Favaro M; Zanatta E; Cardarelli S; Riato L; Punzi L
    Clin Rheumatol; 2013 May; 32(5):679-83. PubMed ID: 23344686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
    Rosato E; Molinaro I; Borghese F; Rossi C; Pisarri S; Salsano F
    J Rheumatol; 2010 Dec; 37(12):2531-9. PubMed ID: 20810512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.
    Humbert M; Cabane J
    Rheumatology (Oxford); 2003 Jan; 42(1):191-3. PubMed ID: 12509640
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
    Cestelli V; Manfredi A; Sebastiani M; Praino E; Cannarile F; Giuggioli D; Ferri C
    Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
    Funauchi M; Kishimoto K; Shimazu H; Nagare Y; Hino S; Yano T; Kinoshita K
    Rheumatol Int; 2009 May; 29(7):769-75. PubMed ID: 19037604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
    Nishibu A; Sakai E; Oyama N; Yamamoto T
    Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
    Sfikakis PP; Papamichael C; Stamatelopoulos KS; Tousoulis D; Fragiadaki KG; Katsichti P; Stefanadis C; Mavrikakis M
    Arthritis Rheum; 2007 Jun; 56(6):1985-93. PubMed ID: 17530638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosentan in systemic sclerosis.
    Heresi GA; Minai OA
    Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
    Shetty N; Derk CT
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
    Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
    Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.
    Bellando-Randone S; Lepri G; Bruni C; Blagojevic J; Radicati A; Cometi L; De Paulis A; Matucci-Cerinic M; Guiducci S
    Clin Rheumatol; 2016 Jan; 35(1):127-32. PubMed ID: 26631100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension.
    Opitz C; Klein-Weigel PF; Riemekasten G
    Vasa; 2011 Jan; 40(1):20-30. PubMed ID: 21283970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval.
    Agard C; Carpentier PH; Mouthon L; Clerson P; Gressin V; Bérezné A; Diot E; Jego P; Lok C; Sparsa A; Chatelus E; Van Kien AK; Quéré I; Sibilia J; Hachulla E
    Scand J Rheumatol; 2014; 43(5):398-402. PubMed ID: 24720440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of bosentan in the treatment of Raynaud's phenomenon in patients with systemic sclerosis never treated with prostanoids.
    Parisi S; Bruzzone M; Centanaro Di Vittorio C; Laganà A; Peroni CL; Fusaro E
    Reumatismo; 2014 Mar; 65(6):286-91. PubMed ID: 24705032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bosentan for treatment of active digital ulcers in patients with systemic sclerosis].
    Launay D; Diot E; Pasquier E; Mouthon L; Boullanger N; Fain O; Jego P; Carpentier P; Hatron PY; Hachulla E
    Presse Med; 2006 Apr; 35(4 Pt 1):587-92. PubMed ID: 16614599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.